Table 2 Immunohistochemical profile of the studied ROC-1,CAIX and p21 in the studied bladder carcinoma cases
From: ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients
Variables | Malignant cases (No = 80) No (%) |
|---|---|
ROC1 expression | |
 Positive | 72 (90%) |
 Negative | 8 (10%) |
|  | No = 72 |
RCO1 subcellular localization | |
 Cytoplamic | 24 (33.3%) |
 Nucleo-cytoplasmic | 48 (66.7%) |
ROC-1 intensity | |
 Predominant strong | 18 (25.0%) |
 Predominant moderate | 30 (41.7%) |
 Predominant mild | 24 (33.3%) |
ROC1 H.score | |
 Low expression | 37 (51.4%) |
 High expression | 35 (48.6%) |
CAX expression | |
 Positive | 49 (92.5%) |
 Negative | 31 (73.8%) |
|  | No = 49 |
CAX subcellular localization | |
 Cytoplamic | 44 (89.7%) |
 Nucleo-cytoplasmic | 5 (10.2%) |
CAIX intensity | |
 Predominant strong |  |
 Predominant moderate |  |
 Predominant mild |  |
CAX H-score | |
 Low expression | 31 (63.3%) |
 High expression | 18 (36.7%) |
P21 expression | |
 Positive | 67 (83.75%) |
  Negative | 13 (16.25%) |
|  | No = 67 |
P21 subcellular localization | |
 Cytoplamic | 55 (82.1%) |
 Nucleo-cytoplasmic | 12 (17.9%) |
P21 intensity | |
 Predominant strong |  |
 Predominant moderate |  |
 Predominant mild |  |
P21 H-score | |
 Low expression | 34 (50.7%) |
 High expression | 49 (92.5%) |